Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells.The symptoms, prognosis, and treatment of a glioma depend on the person’s age, the exact type of tumor, and the location of the tumor within the brain.
This report contains market size and forecasts of Adult Malignant Glioma Therapeutics in Global, including the following market information:
Global Adult Malignant Glioma Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Adult Malignant Glioma Therapeutics market was valued at 1329.5 million in 2021 and is projected to reach US$ 1867.9 million by 2028, at a CAGR of 5.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Glioblastoma Multiforme Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Adult Malignant Glioma Therapeutics include Merck, Hoffmann-La Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceutical and Teva Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adult Malignant Glioma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adult Malignant Glioma Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Adult Malignant Glioma Therapeutics Market Segment Percentages, by Type, 2021 (%)
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Other
Global Adult Malignant Glioma Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Adult Malignant Glioma Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers
Others
Global Adult Malignant Glioma Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Adult Malignant Glioma Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adult Malignant Glioma Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Adult Malignant Glioma Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Hoffmann-La Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceutical
Teva Pharmaceutical
Novocure
Eli Lilly
AstraZeneca
Novartis AG